{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-020313","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.752272+00:00","generated_at":"2026-05-25T12:34:41.495194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel reports 2024 net income $17.5M, record product sales $144.9M, guides FY25 rev $200-210M","bullets":["4Q total revenue $57.6M; TAVALISSE $31.0M (+21% YoY), REZLIDHIA $7.4M (+92% YoY), GAVRETO $8.1M.","FY24 total revenue $179.3M; net product sales $144.9M (+39% YoY); net income $17.5M vs loss $25.1M in FY23.","Cash & short-term investments $77.3M at year-end, up from $56.9M; expects positive net income in FY25.","FY25 guidance: total revenue $200-210M; net product sales $185-192M; contract revenues $15-18M.","R289 granted Fast Track and Orphan Drug designations for MDS; partner TAVALISSE approvals in South Korea and Mexico."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-020313","json":"https://secwatch.observer/filing/0001104659-25-020313.json","markdown":"https://secwatch.observer/filing/0001104659-25-020313.md","text":"https://secwatch.observer/filing/0001104659-25-020313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/0001104659-25-020313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/tm258144d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T12:34:41.495194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}